New drug targets Cancer's genetic weakness in Hard-to-Treat cases
NCT ID NCT05490771
Summary
This study is testing whether a drug called copanlisib can shrink or stop the growth of advanced cancers that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that cancer cells need to grow. The trial includes 35 adults with various advanced cancers that have not responded to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.